SCHEMBL6846100

SCHEMBL6846100

c1cncc(-n2ccc3c(-c4ccoc4)cccc32)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 1/20 0.41
CDK2 P24941 1/20 0.41
IMPDH2 P12268 1/20 0.41
CYP3A4 P08684 7/20 0.40
CYP1A2 P05177 5/20 0.40
HSD17B10 Q99714 4/20 0.40
CYP2C19 P33261 4/20 0.40
MEN1 O00255 3/20 0.40
ALOX15 P16050 3/20 0.40
KMT2A Q03164 3/20 0.40
ALDH1A1 P00352 3/20 0.40
FYN P06241 2/20 0.39
PPARA Q07869 1/20 0.39
CYP2A6 P11509 3/20 0.37
NT5E P21589 1/20 0.37
MAPK14 Q16539 1/20 0.36
CYP2D6 P10635 3/20 0.35
MAPT P10636 2/20 0.35
MAPK1 P28482 2/20 0.35
PRKCI P41743 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6846105 0.84 MAPK14 (0.49) CDC7CDK2CYP3A4CYP1A2HSD17B10
SCHEMBL6847772 0.82 DYRK1A (0.47) CYP3A4CYP1A2HSD17B10ALDH1A1CYP2A6
SCHEMBL6844416 0.81 CDC7 (0.41) CDC7CDK2IMPDH2CYP3A4CYP1A2
SCHEMBL6657827 0.79 CYP17A1 (0.41) CYP3A4CYP1A2HSD17B10CYP2A6MAPK14
SCHEMBL6846191 0.79 DHPS (0.50) CYP3A4CYP1A2ALDH1A1CYP2A6MAPK14
SCHEMBL6844276 0.77 CDC7 (0.44) CDC7CYP1A2ALDH1A1MAPK14MAPT
SCHEMBL6844275 0.76 QPCT (0.46) CYP3A4CYP1A2CYP2C19MEN1KMT2A
SCHEMBL6846026 0.76 KIF11 (0.48) CYP3A4MEN1KMT2AALDH1A1CYP2A6
SCHEMBL6846183 0.75 HSD11B1 (0.45) CDC7CDK2CYP3A4CYP1A2HSD17B10
SCHEMBL6657706 0.74 CYP11B2 (0.43) CYP3A4CYP1A2HSD17B10CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors CYP17A1, IDO1, CYP21A2 CDC7 1627/4885CDK2 732/4885IMPDH2 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.